Technology assessment is a structured process for evaluating whether a new technology, particularly in healthcare, actually delivers enough benefit to justify its costs and risks. Its core purpose is to inform decisions about which technologies get funded, covered by insurance, or adopted into routine practice, so that limited resources go where they do the most good. In healthcare, this process is formally known as Health Technology Assessment (HTA), and it shapes everything from which drugs your insurance covers to which medical devices hospitals purchase.
What Technology Assessment Evaluates
HTA agencies around the world have converged on a core set of criteria they examine for any new health technology. A review of 52 guidelines from 24 countries found strong consensus on four pillars: effectiveness (does it work?), safety (what are the risks?), cost-effectiveness (is it worth the money?), and budget impact (can the system afford it?). These four questions form the backbone of nearly every assessment, regardless of country.
But the evaluation doesn’t stop at clinical and economic factors. The European HTA Core Model, one of the most widely used frameworks, divides its analysis into nine domains: the health problem being addressed, technical characteristics of the technology, safety, clinical effectiveness, economic evaluation, ethical analysis, organizational impact, legal considerations, and patient or social aspects. The ethical domain alone covers 20 distinct issues, including the balance of benefits and harms, patient autonomy, justice and equity, and broader ethical consequences of adoption. The legal domain spans 18 issues ranging from patient privacy to liability and market regulation.
How It Shapes What Gets Covered
The most direct, practical consequence of technology assessment is its influence on whether a treatment or device gets reimbursed. To secure coverage from public or private payers, manufacturers typically need to demonstrate that their technology improves patient outcomes at an acceptable cost compared to whatever is currently available. In many countries, a positive HTA recommendation is essentially a prerequisite for getting funded.
The specifics vary by country. In 19 of 23 European countries studied, the HTA recommendation is forwarded to a separate independent body that makes the final reimbursement decision. In France, for example, the health minister makes the final call based on opinions from two advisory bodies, and the price of a device is then negotiated between a government committee and the manufacturer. In the Netherlands, the national HTA institute advises the health minister on whether to include or exclude devices from the basic insurance package. In Portugal, only devices judged to have equivalent or added value compared to existing options move forward to price negotiation.
Some countries tie reimbursement tightly to HTA results, while others use them as one input among several. A few rely on more informal, case-by-case processes where HTA outcomes don’t necessarily drive the decision.
Measuring Whether a Technology Is Worth the Cost
One of the most important tools in technology assessment is cost-effectiveness analysis, which often boils down to a single metric: how much does it cost to gain one quality-adjusted life year, or QALY. A QALY represents one year of life in perfect health. If a treatment extends life but with significant side effects, each year counts as less than a full QALY.
The UK’s National Institute for Health and Care Excellence (NICE) is the most prominent example of an agency that uses explicit cost-per-QALY thresholds. NICE currently applies a range of £20,000 to £30,000 per QALY gained when deciding whether a treatment represents good value for the National Health Service. The agency has confirmed that new thresholds of £25,000 to £35,000 per QALY will take effect once regulations are updated. Technologies that fall within these ranges are generally recommended for coverage; those that exceed them face greater scrutiny or rejection.
In the United States, there is no centralized government HTA agency. However, the Institute for Clinical and Economic Research (ICER), an independent organization, has adopted cost per QALY as a key metric and increasingly shapes how insurers and policymakers think about value. Traditional cost-effectiveness analyses have focused narrowly on clinical benefits and side effects, though newer approaches are beginning to incorporate broader factors like productivity losses and the burden on caregivers.
The Assessment Process Step by Step
For a manufacturer seeking approval in Europe, the HTA process runs roughly parallel to the regulatory approval process. A company first submits a letter of intent about seven months before the formal assessment begins. An assessment team then defines the scope of the evaluation using a framework called PICO: the patient population, the intervention being assessed, the comparator (existing standard of care), and the outcomes that matter. This scoping phase takes about 78 days and includes a meeting with the company to discuss what evidence is needed.
The company then prepares a dossier of scientific evidence, which takes about 100 days (or 60 for priority cases). After submission, assessors check the dossier for completeness over roughly 36 days, potentially requesting additional data. The entire process from start to final recommendation typically takes nine to 14 months, averaging about one year. The timeline is partly dependent on the regulatory authority’s own review, which can include pauses while the company responds to questions.
Global Resource Allocation and Universal Coverage
Technology assessment plays a particularly important role in countries working toward universal health coverage. The World Health Organization actively supports countries at all income levels in using HTA to make allocation decisions, recognizing that every health system faces resource constraints regardless of wealth. The WHO’s focus is on helping governments achieve the best health outcomes per dollar spent, with special attention to equity and financial protection for patients.
WHO Resolution 67.23 specifically calls for health technology assessment to support universal health coverage. The organization’s work in this area includes developing standardized tools for cost-effectiveness analysis and building global databases of which interventions offer the best value. For low- and middle-income countries, where a single expensive technology could consume a disproportionate share of the health budget, this kind of structured evaluation can be the difference between a well-functioning system and one distorted by a few high-cost treatments.
New Challenges With AI and Digital Health
The rise of artificial intelligence in medicine is pushing technology assessment into unfamiliar territory. Traditional HTA frameworks were designed for drugs and devices that work the same way every time. AI-based technologies can change over time as their algorithms learn from new data, raising questions about how to assess something that may perform differently six months after approval than it did during evaluation.
A panel of experts identified ten priority topics for AI assessment that go beyond standard HTA criteria. At the top of the list: the accuracy of the AI model (rated critical by 98% of panelists), patient safety (96%), and the ethical balance of benefits and harms (96%). Other priorities include data bias, risk management, and how well the AI can explain its decision-making, a property that most current AI systems lack. The existing European HTA Core Model was found to be insufficient for AI technologies, missing 14 of the 20 additional topics experts identified as crucial. Even basic concepts like “explainability” and “trustworthiness” still lack validated, shared definitions across the field.
Europe’s Expanding Regulatory Framework
The European Union is in the process of implementing a new HTA regulation that will standardize joint clinical assessments across all 27 member states. The first phase launched in January 2025, covering advanced therapy medicinal products and cancer treatments. Orphan drugs for rare diseases will be included starting January 2028, and by January 2030, all drugs registered with the European Medicines Agency will fall under the joint assessment process. The goal is consistency: rather than each country conducting its own clinical evaluation from scratch, a single joint assessment will serve as the foundation, while individual countries retain the authority to make their own reimbursement and pricing decisions based on local priorities and budgets.